Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BBLNNASDAQ:BTTXNASDAQ:EUDANASDAQ:REUN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBLNBabylon$0.55$0.60$0.46▼$28.50$14.10M2.42415,159 shsN/ABTTXBetter Therapeutics$0.00$0.00$0.00▼$0.03$5K1.1915,701 shs2,749 shsEUDAEUDA Health$3.50+2.0%$3.80$2.21▼$6.30$130.04M-0.0582,333 shs36,224 shsREUNReunion Neuroscience$1.12$1.12$0.63▼$5.07$13.13M2.29210,209 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBLNBabylon0.00%0.00%0.00%0.00%0.00%BTTXBetter Therapeutics0.00%0.00%-50.00%-50.00%-99.00%EUDAEUDA Health-4.19%-6.77%-9.97%-10.68%+29.43%REUNReunion Neuroscience0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBLNBabylonN/AN/AN/AN/AN/AN/AN/AN/ABTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEUDAEUDA Health0.5991 of 5 stars0.03.00.00.02.90.00.6REUNReunion NeuroscienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBLNBabylon 0.00N/AN/AN/ABTTXBetter Therapeutics 0.00N/AN/AN/AEUDAEUDA Health 4.00Strong BuyN/AN/AREUNReunion Neuroscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBLNBabylon$1.15B0.01N/AN/A($10.29) per share-0.05BTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AEUDAEUDA Health$4.01M32.42N/AN/A($0.30) per share-11.67REUNReunion Neuroscience$3.88M3.38N/AN/A$1.37 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBLNBabylon-$221.45M-$23.03N/A∞N/A-35.54%N/A-105.06%N/ABTTXBetter Therapeutics-$39.76MN/A0.00∞N/AN/AN/AN/A5/30/2025 (Estimated)EUDAEUDA Health-$10.04MN/A0.00N/AN/AN/AN/AN/A5/30/2025 (Estimated)REUNReunion Neuroscience-$36.69MN/A0.00N/AN/AN/A-91.82%-64.58%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBLNBabylonN/AN/AN/AN/AN/ABTTXBetter TherapeuticsN/AN/AN/AN/AN/AEUDAEUDA HealthN/AN/AN/AN/AN/AREUNReunion NeuroscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBLNBabylonN/A1.071.07BTTXBetter TherapeuticsN/AN/AN/AEUDAEUDA HealthN/A0.13N/AREUNReunion NeuroscienceN/A3.513.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBLNBabylon37.90%BTTXBetter Therapeutics34.00%EUDAEUDA Health4.35%REUNReunion Neuroscience12.88%Insider OwnershipCompanyInsider OwnershipBBLNBabylon38.52%BTTXBetter Therapeutics51.40%EUDAEUDA HealthN/AREUNReunion NeuroscienceN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBLNBabylon1,89525.61 million15.75 millionNot OptionableBTTXBetter Therapeutics4049.86 million24.23 millionOptionableEUDAEUDA Health237.15 millionN/ANot OptionableREUNReunion Neuroscience1611.72 millionN/ANot OptionableBBLN, EUDA, REUN, and BTTX HeadlinesRecent News About These CompaniesResearchers at CU Anschutz studying if psilocybin effects can help treat postpartum depressionMay 21, 2025 | msn.comReunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)May 19, 2025 | globenewswire.comLSD for Anxiety and Depression: Worth the Trip?May 8, 2025 | medscape.comPostpartum Depression Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesApril 7, 2025 | theglobeandmail.comReunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the ...April 7, 2025 | bakersfield.comReunion Neuroscience Presents REKINDLE, a Phase 2 Clinical Trial Evaluating RE104 for the Treatment of Adjustment Disorder (AjD) in Cancer and Other Medical Illnesses at the Anxiety & Depression Association of America (ADAA) 2025 ConferenceApril 7, 2025 | globenewswire.comReunion Neuroscience Announces Participation in Premiere Maternal Mental Health EventMarch 4, 2025 | globenewswire.com5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJanuary 23, 2025 | finance.yahoo.comAre Indian brands prepared for neuroscience-backed advertising in 2025?January 7, 2025 | bestmediainfo.comReunion Neuroscience Announces Program Updates and Highlights Anticipated 2025 MilestonesJanuary 6, 2025 | globenewswire.comReunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual MeetingDecember 11, 2024 | globenewswire.comTwenty-First-Century GriefNovember 11, 2024 | psychologytoday.comBeethoven’s Ninth and the Ode to Joy: Symphony and PsycheOctober 14, 2024 | psychologytoday.comReunion Neuroscience Partners with Seleni Institute on Effective Diagnosis and Treatment of Maternal Mental Health DisordersOctober 9, 2024 | globenewswire.comCottage Children’s Medical Center Hosts NICU Reunion at Santa Barbara ZooOctober 3, 2024 | independent.comTo Motivate Teens, Ask “Who’s Your Future Self?”September 18, 2024 | edutopia.orgReunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical OfficerSeptember 10, 2024 | globenewswire.comBringing together world-class neuroscience to advance research and clinical careSeptember 9, 2024 | bristol.ac.ukReunion Neuroscience Joins the Is Mom OK? Initiative Recognizing Maternal Suicide Prevention MonthSeptember 4, 2024 | globenewswire.comApes Have Never Asked Questions Despite Scientists Communicating with Them Since '60s?September 2, 2024 | snopes.comMedia Sentiment Over TimeBBLN, EUDA, REUN, and BTTX Company DescriptionsBabylon NYSE:BBLNBabylon Holdings Limited operates as a digital healthcare company. It offers end-to-end care solution that facilities through its digital health suite, virtual care, in-person medical care, and post-care offerings. The company provides Babylon Cloud and clinical services. Babylon Holdings Limited was founded in 2013 and is headquartered in Austin, Texas.Better Therapeutics NASDAQ:BTTX$0.0001 0.00 (0.00%) As of 09:34 AM EasternBetter Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.EUDA Health NASDAQ:EUDA$3.50 +0.07 (+2.04%) Closing price 03:59 PM EasternExtended Trading$3.63 +0.13 (+3.71%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.Reunion Neuroscience NASDAQ:REUNReunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
